{"id":8882,"date":"2023-07-11T11:53:16","date_gmt":"2023-07-11T03:53:16","guid":{"rendered":"https:\/\/ttic.nhri.edu.tw\/?p=8882"},"modified":"2023-07-11T11:53:16","modified_gmt":"2023-07-11T03:53:16","slug":"technology-available-for-industry-academia-collaboration-or-technology-licensing-taiwan-polycystic-kidney-disease2023-7-10","status":"publish","type":"post","link":"https:\/\/ttic.nhri.edu.tw\/en\/technology-available-for-industry-academia-collaboration-or-technology-licensing-taiwan-polycystic-kidney-disease2023-7-10\/","title":{"rendered":"Technology Available for Industry-Academia Collaboration or Technology Licensing. \u201cTaiwan Polycystic Kidney Disease\u201d(2023\/7\/10)"},"content":{"rendered":"

Technology Available for Industry-Academia Collaboration or Technology <\/strong>Licensing. \u201cTaiwan Polycystic Kidney Disease\u201d<\/strong><\/p>\n

Date: 2023.7.10<\/p>\n

1.Title:<\/p>\n

NHRI technology, \u201cTaiwan Polycystic Kidney Disease\u201d (abbreviated as\u201cThe Technology<\/strong>\u201d) available for industry-academia collaboration or technology licensing.<\/p>\n

2.Description:<\/p>\n

Autosomal Dominant polycystic kidney disease (ADPKD) is the most common inherited adult kidney disease. Although ADPKD is primarily caused by PKD1<\/em> and PKD2<\/em>, the identification of several novel causative genes in recent years has revealed more complex genetic heterogeneity than previously thought. To study the disease-causing mutations of ADPKD, a total of 920 families were collected and their diagnoses were established via clinical and image studies by Taiwan PKD Consortium investigators. Disease-causing mutations were identified in 634 families (68.9%) by detection of 364 PKD1<\/em>, 239 PKD2<\/em>, 18 PKHD1<\/em>, 7 GANAB<\/em>, and 6 ALG8<\/em> pathogenic variants. 162 families (17.6%) had likely causative but non-diagnostic variants of unknown significance (VUS). A single PKD2 p.Arg803* mutation was found in 17.8% (164\/920) of the cohort in Taiwan.<\/p>\n

We are soliciting companies for industry- academia collaboration related to ethnic genes in Taiwan cohort.<\/p>\n

3.Potential collaboration partner qualifications:<\/p>\n

(1)\u00a0\u00a0\u00a0\u00a0\u00a0be incorporated and approved by law and does not have any record of misconduct or conviction for any offense<\/p>\n

(2)\u00a0\u00a0\u00a0\u00a0\u00a0better to have related experience and skills for developing The Technology<\/strong><\/p>\n

(3)\u00a0\u00a0\u00a0\u00a0\u00a0better to have experience of international collaboration and clinical trial<\/p>\n

(4)\u00a0\u00a0\u00a0\u00a0\u00a0better to be ready to invest or be able to raise the funds<\/p>\n

4.Registration\uff1a<\/p>\n

Please contact to Ms. Wan-Ping Hsieh (Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan, R.O.C., Tel:+88637-246166 # 33227, E-mail: wanping@nhri.edu.tw<\/a>).<\/p>\n

5.Other:<\/p>\n